1. Home
  2. BGLC vs PULM Comparison

BGLC vs PULM Comparison

Compare BGLC & PULM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$2.32

Market Cap

10.1M

Sector

Health Care

ML Signal

N/A

Logo Pulmatrix Inc.

PULM

Pulmatrix Inc.

HOLD

Current Price

$1.22

Market Cap

9.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGLC
PULM
Founded
2017
2003
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.1M
9.4M
IPO Year
2019
2013

Fundamental Metrics

Financial Performance
Metric
BGLC
PULM
Price
$2.32
$1.22
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
5.8K
74.5K
Earning Date
05-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
45.78
46.18
EPS
N/A
N/A
Revenue
$9,510,646.00
$7,910,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5069.93
52 Week Low
$0.23
$1.32
52 Week High
$15.19
$9.37

Technical Indicators

Market Signals
Indicator
BGLC
PULM
Relative Strength Index (RSI) 43.18 27.61
Support Level $2.12 N/A
Resistance Level $2.73 $4.97
Average True Range (ATR) 0.11 0.15
MACD 0.01 -0.09
Stochastic Oscillator 34.31 1.57

Price Performance

Historical Comparison
BGLC
PULM

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of different diseases.

About PULM Pulmatrix Inc.

Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).

Share on Social Networks: